Gabriel C M, Howard R, Kinsella N, Lucas S, McColl I, Saldanha G, Hall S M, Hughes R A
Department of Neuroimmunology, Guy's, King's and St Thomas' School of Medicine, King's College, London, UK.
J Neurol Neurosurg Psychiatry. 2000 Oct;69(4):442-6. doi: 10.1136/jnnp.69.4.442.
This study aimed to determine the usefulness of sural nerve biopsy in neurological practice.
The first prospective study of sural nerve biopsy in 50 consecutive patients was undertaken. The investigating neurologist declared the prebiopsy diagnosis and management plan and after 3 months an independent neurologist evaluated the contribution of the biopsy to diagnosis and management. An independent audit officer sought information from the patient about the adverse effects and value of the biopsy after 6 weeks and 6 months.
In seven cases the nerve biopsy changed the diagnosis, in 35 cases the biopsy confirmed the suspected diagnosis, and in eight cases the biopsy was non-contributory. The biopsy either changed or was helpful in guiding patient management in 60%, especially those with demyelinating neuropathy and multiple mononeuropathy. Seven patients reported having had infection and 10 reported increased pain at the biopsy site 6 months later.
In a consecutive series of 50 cases, sural nerve biopsy altered the diagnosis in 14%, affected management in 60%, and caused persistent increased pain at the biopsy site in 33%.
本研究旨在确定腓肠神经活检在神经科临床实践中的作用。
对连续50例患者进行了首次腓肠神经活检前瞻性研究。负责研究的神经科医生宣布活检前的诊断和管理计划,3个月后由一名独立神经科医生评估活检对诊断和管理的贡献。一名独立审计人员在6周和6个月后向患者询问活检的不良反应和价值。
7例患者经神经活检后诊断改变,35例患者活检证实了疑似诊断,8例患者活检无帮助。活检改变或有助于指导60%患者的管理,尤其是那些患有脱髓鞘性神经病和多发性单神经病的患者。7例患者报告发生感染,10例患者报告6个月后活检部位疼痛加剧。
在连续50例病例中,腓肠神经活检使14%的患者诊断改变,60%的患者治疗受到影响,33%的患者活检部位疼痛持续加剧。